A group of mothers in Victoria say they've experienced trouble accessing the jab for a highly infectious illness that infects ...

Canada hosted ITF Masters events in Mont-Tremblant and Ottawa over the past month, with the hosts dominating the latter.

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Medical staff in Western Australia have been warned after reports of the wrong immunisations being given to patients. The ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

Pfizer ’s PFE Abrysvo is approved for the prevention of RSV-associated LRTD in all individuals aged 60 years and above, as well as in infants, through maternal immunization.

Pfizer is also running a phase 3 trial of Abrysvo in adults aged 18 to 59 at elevated risk of RSV disease due to chronic medical conditions, but data from that isn't due until later this year.

These include Pfizer ’s PFE Abrysvo, and GSK’s Arexvy. Arexvy and Abrysvo are approved by the FDA for use in all individuals aged 60 and above.

Abrysvo also is approved for prevention of LRTD caused by RSV in adults ages 18 to 59 years who are at increased risk, and for immunization in pregnancy at 32 to 36 weeks' gestational age for the ...